Crossmark

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Crossref DOI link: https://doi.org/10.1038/leu.2016.90

Published Online: 2016-04-25

Published Print: 2016-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cross, N C P

White, H E

Ernst, T

Welden, L

Dietz, C

Saglio, G

Mahon, F-X

Wong, C C

Zheng, D

Wong, S

Wang, S-S

Akiki, S

Albano, F

Andrikovics, H

Anwar, J

Balatzenko, G

Bendit, I

Beveridge, J

Boeckx, N

Cerveira, N

Cheng, S-M

Colomer, D

Czurda, S

Daraio, F

Dulucq, S

Eggen, L

El Housni, H

Gerrard, G

Gniot, M

Izzo, B

Jacquin, D

Janssen, J J W M

Jeromin, S

Jurcek, T

Kim, D-W

Machova-Polakova, K

Martinez-Lopez, J

McBean, M

Mesanovic, S

Mitterbauer-Hohendanner, G

Mobtaker, H

Mozziconacci, M-J

Pajič, T

Pallisgaard, N

Panagiotidis, P

Press, R D

Qin, Y-Z

Radich, J

Sacha, T

Touloumenidou, T

Waits, P

Wilkinson, E

Zadro, R

Müller, M C

Hochhaus, A

Branford, S
License Information

Text and Data Mining valid from 2016-04-25
More Information

Article History

Received: 22 March 2016

Accepted: 11 April 2016

First Online: 25 April 2016

Competing interests

: This study was designed and funded by Novartis Pharmaceuticals Corporation. CW, DZ, SW and SSW are employed by Novartis Pharmaceuticals Corporation. None of the co-authors, participating laboratories or institutions received any payments for participating in this study. All authors have read and agreed with the contents of the manuscript. All other authors declare no conflicts of interest.